|Bid||66.81 x 2900|
|Ask||67.17 x 1400|
|Day's Range||66.57 - 67.35|
|52 Week Range||53.63 - 71.70|
|Beta (5Y Monthly)||0.10|
|PE Ratio (TTM)||124.04|
|Forward Dividend & Yield||1.44 (2.15%)|
|Ex-Dividend Date||Feb 24, 2022|
|1y Target Est||72.70|
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.